Format

Send to

Choose Destination
Sci Rep. 2019 Jan 24;9(1):564. doi: 10.1038/s41598-018-37252-9.

Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease.

Lee J1,2,3, Kwon SJ4, Kim JH3, Jang H5,2, Lee NK1,2,3, Hwang JW1,2,3, Kim JH6, Chang JW7,8,9, Na DL10,11,12,13.

Author information

1
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
2
Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea.
3
Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea.
4
R&D Center, ENCell Co.Ltd, Seoul, Republic of Korea.
5
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
6
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
7
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. Changjw@skku.edu.
8
Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea. Changjw@skku.edu.
9
R&D Center, ENCell Co.Ltd, Seoul, Republic of Korea. Changjw@skku.edu.
10
Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea. dukna@skku.edu.
11
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. dukna@skku.edu.
12
Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea. dukna@skku.edu.
13
Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul, Republic of Korea. dukna@skku.edu.

Abstract

Mesenchymal stem cells (MSCs) have emerged as one of the promising treatment options for Alzheimer's disease (AD). Although many studies have investigated on the efficacy of MSCs in AD, how MSCs actually change following exposure to the AD environment has not been studied extensively. In this study, we investigated on the potential of AD patient-cerebrospinal fluid (CSF) samples to be used as a formulation of MSCs and its application in AD therapeutics. When Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) were stored in the CSF of AD patients, the stemness of WJ-MSCs was preserved. Furthermore, several genes were upregulated following storage in AD CSF. This signified the therapeutic potential of CSF formulation for AD therapy. Overall, these findings suggest that CSF from AD patients can be an optimal source for MSC formulation.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center